Introduction
Millions of lives are saved each year through blood transfusion but, a safe blood is a critical component of health care to prevent the spread of blood borne infectious diseases. Safe blood is a continuing concern especially in developing countries where 80% of the world population lives. General lack of quality systems, poor laboratory procedures, inadequate testing of donated blood, inappropriate use of blood and blood components may contribute for unsafe blood transfusion services. Burden of the disease and loss of life resulting from unsafe blood transfusions is very serious problem for the communities in developing countries. The transfusion transmissible infections (TTI) like hepatitis B, hepatitis C, HIV, malaria and syphilis etc. were first observed in the process of blood transfusion in the late 1940s. Hepatitis B is a global problem, with 66 percent of the entire world's population living in areas where there are high levels of infection. More than 2 billion people in the world have evidence of past or current HBV infection and 350 million are chronic carriers of the virus, which is harboured in the liver and causes an estimated 6,20,000 deaths. The virus causes 60 to 80 percent of all primary liver cancer, which is one of the three top causes of cancer death in east and South East Asian region, the Pacific Basin and sub Saharan Africa. [1] HCV was identified in the year 1989. World Health Organization (WHO) estimates that 3 percent of the world population is infected with HCV and around 170 million individuals are chronic carriers at risk of developing liver cirrhosis and liver cancer. [1, 2] In our study, the seroprevalence of HBV and HCV was determined in clinically healthy blood donors and trend was noted with respect to type of donor, age, sex, blood group of donor. 
Materials and Methods
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to replace blood used or expected to be used for the patients from the blood bank. In the blood bank donors were screened by targeted questionnaire and by medical examination. Clinically healthy individuals of 18 to 65 years of age with body weight more than 45 kg and haemoglobin more than 12.5 g/dl were qualified for donation. Sera of these qualified blood donors were screened for hepatitis B surface antigen (HBsAg) and IgG antibodies to HCV by using commercially available (J Mitra & Co Pvt Ltd New Delhi) Enzyme Linked Immunosorbent Assay (ELISA) kits. The procedure of test was followed according to manufacturer's instruction. The positive sera and random negative samples were retested by ELISA in Bapuji blood bank Davangere in order to assure the quality of in house by external peer.
Data were entered and analyzed by using SPSS version 13 statistical package. Prevalence of HBV and HCV was noted with respect to age, sex, type of donor, year and the blood group. Significance of the trend was determined by chi square test.
Results
A total number of 19,413 donors were screened during the study period. Of these 19,189 (99%) were males and 224 (1%) were females. Ninety four percent of donors were replacement donors and 46.13% of donors belonged to the age group 18 to 25 years. O positive was the commonest blood group observed. (Figure 1 ). Association of prevalence with year was insignificant. The blood transfusion is an effective mode of transmission of both HBV and HCV, as it allows large quantum of infective virions into the recipient. Pre-donation clinical screening of donors to reject or defer the risky group from donation is an important step. But many of the donors are not detected during pre-donation clinical screening by blood bank officer especially, if the persons are, in window period of the disease or in convalescent phase or asymptomatic cases or carriers. The seroprevalence of HBV and HCV is more in replacement donors than in voluntary donors. The reason could be the obligatory motto behind the donation in case of replacement donors, who might hide their disease during pre-donation clinical screening. This observation is supported by many other studies. [3] [4] [5] In our study seroprevalence of HBV was more in replacement donors but, the association was statistically insignificant. This finding could be because of very low proportion (06%) of voluntary blood donors in our study. However, a change from replacement donors to 100% voluntary blood donation is required in every blood bank to reduce risk of TTI. This may be achieved by creating public awareness about voluntary blood donation and its benefits.
In our study, the seroprevalence of HBV was increasing significantly with the age of donor. This could be because of less number of donors belonging to the age group of 60 to 65 years. The seroprevalence of HBV and HCV in blood donors of various countries and in different parts of India is given in the Table 3 In US, Japan and France anti HBc was made mandatory in 1980s. Due to false positivity of Anti HBc assay tests, HBV NAT was introduced in many western countries to overcome the window phase of HBsAg assays. [20] In the view of high prevalence of hepatitis B, it is worth to implement the use of anti HBc assay along with assay of HBsAg in order to prevent post transfusion hepatitis to a certain extent.
Conclusion
This study has determined prevalence of HBV infection of 2.12% and HCV infection of 0.1% among blood donors of Central Karnataka. Seroprevalence of HBV was higher among replacement donors. Hence, to reduce the prevalence of post-transfusion hepatitis, stringent donor screening procedure and 100% voluntary blood donations may be effective. Routine screening for HBV & HCV in blood banks should be performed using sensitive ELISA methods.
